MetaCap

Cytokinetics (CYTK) vs Mirum Pharmaceuticals (MIRM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mirum Pharmaceuticals (MIRM) has outperformed Cytokinetics (CYTK) over the past year, gaining 35.5% versus a loss of 22.4%. Over five years, MIRM leads with a +616.9% price change compared with +30.1% for CYTK. Cytokinetics is the larger company by market cap ($7.07 billion vs $6.28 billion), about 1.1 times the size.

Mirum Pharmaceuticals converts more of its revenue into profit, with a net margin of -4.5% versus -891.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CYTK-22.40%MIRM+35.45%
+86%+29%-28%
Nov 21, 20251 yearNov 20, 2026
CYTK+24.28%MIRM+512.68%
+737%+336%-64%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CYTK versus MIRM key metrics
MetricCYTKMIRM
Share price$50.78$96.13
Market cap$7.07B$6.28B
1-day change-1.32%+0.65%
YTD return-20.08%+21.70%
1-year return-22.40%+35.45%
5-year return+30.11%+616.85%
Forward P/E—300.41
EPS (TTM)$-6.02$-14.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$88.04M$521.31M
Revenue growth (YoY)+376.56%+54.74%
Net income (latest FY)$-784.96M$-23.36M
Operating margin-695.44%-4.25%
Net margin-891.60%-4.48%
52-week high$88.31$130.00
52-week low$50.32$63.23
Distance from 52-week high-42.50%-26.05%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+115.48%+64.06%
Average volume2.02M692.51K
Shares outstanding139.30M65.28M
Employees673470
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MIRM has outperformed CYTK by 57.9 percentage points over the past year.
  • Mirum Pharmaceuticals is more profitable, keeping -4.5 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
  • Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +54.74%).

About Cytokinetics

CYTK stock →

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.

Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees

About Mirum Pharmaceuticals

MIRM stock →

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 470 employees

CYTK vs MIRM FAQ

Which is bigger, Cytokinetics or Mirum Pharmaceuticals?

Cytokinetics (CYTK) is larger, with a market capitalization of $7.07B compared with $6.28B for Mirum Pharmaceuticals (MIRM).

Which stock has performed better over the past year, CYTK or MIRM?

MIRM returned +35.45% over the past 12 months, compared with -22.40% for CYTK (price return, excluding dividends). Past performance does not predict future results.

Are Cytokinetics and Mirum Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons